Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been given an average rating of “Moderate Buy” by the eighteen research firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price target among analysts […]
Los Angeles Capital Management LLC decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 73.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 244,487 shares of the biotechnology company’s stock after selling 683,012 shares during the period. Los Angeles […]
Los Angeles Capital Management LLC lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 73.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 244,487 shares of the biotechnology company’s stock after selling 683,012 shares during the quarter. Los Angeles Capital […]
LSV Asset Management lowered its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 18.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,037,640 shares of the biotechnology company’s stock after selling 229,835 shares during the period. LSV Asset Management owned 0.33% of Exelixis worth $22,672,000 […]
Principal Financial Group Inc. trimmed its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,186,512 shares of the biotechnology company’s stock after selling 47,810 shares during the period. Principal […]